Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database

References

• Kandimalla R, John A, Abburi C, Vallamkondu J, Reddy PH. Current Status of Multiple Drug Molecules, and Vaccines: an Update in SARS-CoV-2 Therapeutics. Mol Neurobiol. 2020;57(10):4106–4116. doi:10.1007/s12035-020-02022-032671688
   PubMed Web of Science ®Google Scholar
• Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N Engl J Med. 2020;382(13):1199–1207. doi:10.1056/NEJMoa200131631995857
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19-11 March 2020. Accessed 102, 2020 https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020.
   Google Scholar
• Ghinai I, McPherson TD, Hunter JC, et al. First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. Lancet. 2020;395(10230):1137–1144. doi:10.1016/s0140-6736(20)30607-332178768
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard [Updated Oct 4, 2020]. Accessed 106, 2020 https://covid19.who.int/.
   Google Scholar
• Nussbaumer-Streit B, Mayr V, Dobrescu AI, et al. Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. Cochrane Database Syst Rev. 2020;4(4):Cd013574. doi:10.1002/14651858.Cd01357432267544
   PubMed Web of Science ®Google Scholar
• Y LZ N, Chua YX, Chaw WL, et al. Evaluation of the Effectiveness of Surveillance and Containment Measures for the First 100 Patients with COVID-19 in Singapore - January 2-February 29, 2020. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep. 2020;69:307–311. doi:10.15585/mmwr.mm6911e132191691
   PubMed Web of Science ®Google Scholar
• Bedford J, Enria D, Giesecke J, et al. COVID-19: towards controlling of a pandemic. Lancet. 2020;395(10229):1015–1018. doi:10.1016/s0140-6736(20)30673-532197103
   PubMed Web of Science ®Google Scholar
• Courtemanche C, Garuccio J, Le A, Pinkston J, Yelowitz A. Strong Social Distancing Measures In The United States Reduced The COVID-19 Growth Rate. Health Affairs. 2020;39(7):1237–1246. doi:10.1377/hlthaff.2020.0060832407171
   PubMed Web of Science ®Google Scholar
• Pradhan D, Biswasroy P, Kumar Naik P, Ghosh G, Rath GA. A Review of Current Interventions for COVID-19 Prevention.Arch Med Res. 2020;51(5):363–374. doi:10.1016/j.arcmed.2020.04.02032409144
   PubMed Web of Science ®Google Scholar
• Ogunleye OO, Basu D, Mueller D, et al. Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: successes, Challenges, and Implications for the Future. Front Pharmacol. 2020;11:1205. doi:10.3389/fphar.2020.0120533071775
   PubMed Web of Science ®Google Scholar
• World Health Organization. COVID-19 Strategic Preparedness and Response Plan - Operational planning guidelines to support country preparedness and response. 2020 Accessed 106, 2020 https://www.who.int/docs/default-source/coronaviruse/covid-19-sprp-unct-guidelines.pdf.
   Google Scholar
• Holder K, Reddy PH, The COVID-19. Effect on the Immune System and Mitochondrial Dynamics in Diabetes, Obesity, and Dementia. Neuroscientist. 2020;1073858420960443. doi:10.1177/107385842096044332981462
   PubMed Web of Science ®Google Scholar
• World Health Organization. Draft landscape of COVID-19 candidate vaccines. Accessed 108, 2020 2020 https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
   Google Scholar
• Mullard ACOVID-19. COVID-19 vaccine development pipeline gears up. Lancet. 2020;395(10239):1751–1752. doi:10.1016/s0140-6736(20)31252-632505245
   PubMed Web of Science ®Google Scholar
• Wu R, Wang L, Kuo HD, et al. An Update on Current Therapeutic Drugs Treating COVID-19. Curr Pharmacol Rep. 2020:1–15. doi:10.1007/s40495-020-00216-7
   PubMedGoogle Scholar
• World Health Organization. SARS (Severe Acute Respiratory Syndrome). https://www.who.int/ith/diseases/sars/en/. Accessed 108, 2020
   Google Scholar
• World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV). Accessed 1010, 2020 https://www.who.int/health-topics/middle-east-respiratory-syndrome-coronavirus-mers#tab=tab_1.
   Google Scholar
• Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574. doi:10.1016/s0140-6736(20)30251-832007145
   PubMed Web of Science ®Google Scholar
• PubChem. Favipiravir. Bethesda (MD): National Library of Medicine (US) https://pubchem.ncbi.nlm.nih.gov/compound/Favipiravir. Accessed 1010, 2020.
   Google Scholar
• Dauby N. Favipiravir as an antiviral agent in COVID-19: same script, different cast? Clinical Infectious Diseases. 2020;ciaa1600. doi:10.1093/cid/ciaa160033075124
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. doi:10.1038/s41422-020-0282-032020029
   PubMed Web of Science ®Google Scholar
• Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic? J Virus Erad. 2020;6(2):45–51. doi:10.1016/s2055-6640(20)30016-932405421
   PubMed Web of Science ®Google Scholar
• Furuta Y, Takahashi K, Kuno-Maekawa M, et al. Mechanism of action of T-705 against influenza virus. Antimicrobial Agents and Chemotherapy. 2005;49(3):981–986. doi:10.1128/aac.49.3.981-986.200515728892
   PubMed Web of Science ®Google Scholar
• Hayden FG, Shindo N. Influenza virus polymerase inhibitors in clinical development. Current Opinion in Infectious Diseases. 2019;32(2):176–186. doi:10.1097/qco.000000000000053230724789
   PubMed Web of Science ®Google Scholar
• Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proceedings of the Japan Academy, Series B. 2017;93(7):449–463. doi:10.2183/pjab.93.027
   Google Scholar
• Borobia AM, Mora-Rillo M, Ramírez Olivencia G, et al. High dose favipiravir: first experience in a patient with Ebola. Clinical Therapeutics. 2015;37(8):e15. doi:10.1016/j.clinthera.2015.05.054
   Web of Science ®Google Scholar
• Ghasemiyeh P, Borhani-Haghighi A, Karimzadeh I, et al. Major Neurologic Adverse Drug Reactions, Potential Drug-Drug Interactions, and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review. Ther Clin Risk Manag. 2020;16:595–605. doi:10.2147/tcrm.S25915232669846
   PubMed Web of Science ®Google Scholar
• Cai Q, Yang M, Liu D, et al. Experimental Treatment with Favipiravir for COVID-19: an Open-Label Control Study. Engineering. 2020. doi:10.1016/j.eng.2020.03.007
   Web of Science ®Google Scholar
• Uppsala Monitoring Centre: WHO Programme for International Drug Monitoring. VigiBase. Accessed 1012, 2020 https://www.who-umc.org/vigibase/vigibase/.
   Google Scholar
• Uppsala Monitoring Centre. VigiBase: signaling harm and pointing to safer use. Accessed 1012 2020 https://www.who-umc.org/vigibase/vigibase/vigibase-signalling-harm-and-pointing-to-safer-use/.
   Google Scholar
• World Health Organization. WHO Collaborating Centre for Drug Statistics Methodology. Accessed 1012, 2020 https://www.whocc.no/.
   Google Scholar
• Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109–117. doi:10.2165/00002018-199920020-0000210082069
   PubMed Web of Science ®Google Scholar
• International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Medical Dictionary for Regulatory Activities(MedDRA). https://www.meddra.org/how-to-use/support-documentation/english/welcome. Accessed 1014, 2020
   Google Scholar
• International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). MedDRA Hierarchy. Accessed 1014, 2020 https://www.meddra.org/how-to-use/basics/hierarchy.
   Google Scholar
• Uppsala Monitoring Centre. Glossary of pharmacovigilance terms. Accessed 1014, 2020 https://www.who-umc.org/global-pharmacovigilance/publications/glossary/.
   Google Scholar
• Bhatti JS, Bhatti GK, Khullar N, Reddy AP, Reddy PH. Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection. Mol Neurobiol. 2020;57(11):4856–4877. doi:10.1007/s12035-020-02074-232808122
   PubMed Web of Science ®Google Scholar
• Chen X, Zhao B, Qu Y, et al. Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease 2019. Clin Infect Dis. 2020;71(8):1937–1942. doi:10.1093/cid/ciaa44932301997
   PubMed Web of Science ®Google Scholar
• Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine. 2020;46(5):846–848. doi:10.1007/s00134-020-05991-x32125452
   PubMed Web of Science ®Google Scholar
• Takahashi H, Iwasaki Y, Watanabe T, et al. Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition. Int J Infect Dis. 2020;100:283–285. doi:10.1016/j.ijid.2020.08.04732829044
   PubMed Web of Science ®Google Scholar
• Yamamura H, Matsuura H, Nakagawa J, Fukuoka H, Domi H, Chujoh S. Effect of favipiravir and an anti-inflammatory strategy for COVID-19. Crit Care. 2020;24(1):413. doi:10.1186/s13054-020-03137-532646499
   PubMed Web of Science ®Google Scholar
• Takahashi K, Furuta Y, Fukuda Y, et al. In Vitro and in Vivo Activities of T-705 and Oseltamivir against Influenza Virus. Antiviral Chemistry and Chemotherapy. 2003;14(5):235–241. doi:10.1177/09563202030140050214694986
   PubMedGoogle Scholar
• Dauby N, Van Praet S, Vanhomwegen C, Veliziotis I, Konopnicki D, Roman A Tolerability of favipiravir therapy in critically ill patients with COVID-19: A report of four cases. J Med Virol. 2020 1–3.doi:10.1002/jmv.2648831502247
   PubMedGoogle Scholar
• Irie K, Nakagawa A, Fujita H, et al. Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19. Clin Transl Sci. 2020;13(5):880–885. doi:10.1111/cts.1282732475019
   PubMed Web of Science ®Google Scholar
• Chinello P, Petrosillo N, Pittalis S, Biava G, Ippolito G, Nicastri E. QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient. PLoS Negl Trop Dis. 2017;11(12):e0006034. doi:10.1371/journal.pntd.000603429283993
   PubMedGoogle Scholar
• Malvy D, Taburet AM, de Lamballerie X, Mentre F, Extramiana F. The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers. PLoS Negl Trop Dis. 2020;14(6):e0008259. doi:10.1371/journal.pntd.000825932584817
   PubMed Web of Science ®Google Scholar
• Madelain V, Nguyen TH, Olivo A, et al. Ebola Virus Infection: review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in. Trials HE. Clin Pharmacokinet. 2016;55(8):907–923. doi:10.1007/s40262-015-0364-126798032
   PubMed Web of Science ®Google Scholar
• AVIGAN. Favipiravir: prescribing information. 2017 Accessed 1014, 2020 https://www.cdc.gov.tw/File/Get/ht8jUiB_MI-aKnlwstwzvw.
   Google Scholar
• Li L, Wang X, Wang R, Hu Y, Jiang S, Lu X. Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients. Drug Des Devel Ther. 2020;14:3001–3013. doi:10.2147/dddt.S259058
   PubMed Web of Science ®Google Scholar
• Chen C, Zhang Y, Huang J, et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv. 2020;20.
   Google Scholar
• Şimşek Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci. 2020;50(SI–1):611–619. doi:10.3906/sag-2004-14532293834
   PubMed Web of Science ®Google Scholar
• Vallamkondu J, John A, Wani WY, et al. SARS-CoV-2 pathophysiology and assessment of coronaviruses in CNS diseases with a focus on therapeutic targets Biochim Biophys. Acta Mol Basis Dis. 2020;1866(10):165889. doi:10.1016/j.bbadis.2020.165889
   PubMed Web of Science ®Google Scholar